Pancreatic Cancer Research

ResearcherOita UniversityActive in the last 2 years

Teijiro Hirashita

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0252-0494; OpenAlex author ID A5052078964. Sources: OpenAlex.

Their work

Papers
14 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
52
Papers, trials and grants by year

2020: 1 paper · 2021: 3 papers · 2022: 1 paper · 2023: 2 papers · 2024: none · 2025: 2 papers · 2026: 5 papers

Papers 14

  1. Outcomes of Resected Cases of Pancreatic Ductal Adenocarcinoma Patients With Unexpected Postoperative Uncovering Noncurative Factors: A Multicenter Retrospecti… Co-author DOI 10.1002/ags3.70090↗
  2. Annexin A8 Drives MEK Inhibitor Resistance, Providing a Druggable Target for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1535-7163.mct-25-0638↗
  3. Pancreatoduodenectomy for Pancreatic Cancer after Prior Modified Puestow Procedure: A Case Report. First author DOI 10.70352/scrj.cr.25-0821↗
  4. Ectopic Pancreatic Adenocarcinoma Arising in the Mesentery of the Jejunum: A Case Report. First author DOI 10.70352/scrj.cr.26-0120↗
  5. Pancreatic Cancer with Concomitant Median Arcuate Ligament Syndrome Requiring Arterial Reconstruction During Pancreaticoduodenectomy: A Case Report. First author DOI 10.70352/scrj.cr.26-0185↗
  6. Patients With Pancreatic Cancer With Synchronous Liver Oligometastasis Show a Significant Long-Term Survival Benefit From Resection Under Specific Conditions: … Co-author DOI 10.1002/jhbp.12181↗
  7. Benefits of neoadjuvant chemotherapy with gemcitabine plus S-1 for resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/mco.2024.2813↗
  8. Involvement of clusterin expression in the refractory response of pancreatic cancer cells to a MEK inhibitor. Co-author DOI 10.1111/cas.15735↗
  9. Technical and oncological safety of pancreatectomy for pancreatic cancer in older adults aged over 75 years versus younger adults: A single-center retrospectiv… Co-author DOI 10.1111/ggi.14622↗
  10. Surgical and oncological outcomes of laparoscopic versus open radical antegrade modular pancreatosplenectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00595-021-02326-1↗
  11. Relationship between the tumor location and clinicopathological features in left-sided pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00595-020-02151-y↗
  12. Downregulation of ZNF395 Drives Progression of Pancreatic Ductal Adenocarcinoma through Enhancement of Growth Potential. Co-author DOI 10.1159/000514593↗
  13. [Long‒Term Survival after Lung Resection for Lung Metastasis of Pancreatic Cancer-A Report of Two Cases]. First author PMID 34006715↗
  14. Fucosyltransferase 8 plays a crucial role in the invasion and metastasis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00595-019-01953-z↗

Closest collaborators

The 25 strongest of 52 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Masafumi Inomata · 12 shared papers, 2020–2026 · strength 2.29
  2. Yuiko Nagasawa · 4 shared papers, 2025–2026 · strength 1.09
  3. Wataru Miyoshino · 3 shared papers, 2026 · strength 0.85
  4. Atsuro Fujinaga · 5 shared papers, 2021–2025 · strength 0.84
  5. Naoki Hijiya · 3 shared papers, 2021–2026 · strength 0.51
  6. Masatsugu Moriyama · 3 shared papers, 2021–2026 · strength 0.51
  7. Shusaku Kurogi · 3 shared papers, 2021–2026 · strength 0.51
  8. Kazuhiro Tada · 3 shared papers, 2020–2025 · strength 0.49
  9. Masafumi Nakamura · 2 shared papers, 2025–2026 · strength 0.39
  10. Izuru Furusho · 1 shared paper, 2026 · strength 0.27
  11. Tsutomu Daa · 1 shared paper, 2026 · strength 0.27
  12. Kazunari Murakami · 2 shared papers, 2021–2023 · strength 0.25
  13. Toru Hisaka · 1 shared paper, 2026 · strength 0.23
  14. Yasuhisa Mori · 1 shared paper, 2026 · strength 0.23
  15. Hiromitsu Hayashi · 1 shared paper, 2026 · strength 0.23
  16. Tomoharu Yoshizumi · 1 shared paper, 2026 · strength 0.23
  17. Hiroaki Nagano · 1 shared paper, 2026 · strength 0.23
  18. Susumu Eguchi · 1 shared paper, 2026 · strength 0.23
  19. Hirokazu Noshirο · 1 shared paper, 2026 · strength 0.23
  20. Hiroto Matsui Matsui · 1 shared paper, 2026 · strength 0.23
  21. Shingo Kozono · 1 shared paper, 2026 · strength 0.23
  22. Hirohisa Okabe · 1 shared paper, 2026 · strength 0.23
  23. Naoki Ikenaga · 1 shared paper, 2026 · strength 0.23
  24. Takeshi Sudo · 1 shared paper, 2025 · strength 0.16
  25. Hiroaki Nagano · 1 shared paper, 2025 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.